Ihre Browserversion ist veraltet. Wir empfehlen, Ihren Browser auf die neueste Version zu aktualisieren.

Previous Meetings 

May 28-31, 2017 

5th World conference on Research Integrity

This conferences focuses on the the interlinked themes of transparency and accountability, discussing possibilities to openly share research and taking personal responsibility. In this line, one goal of this conference will be to develop the Amsterdam Agenda for Promoting Transparency and Accountability. 

PAASP will be presenting a poster and a talk at this conference.

Short commentary in our June Newsletter.


June 1, 2017

Anton Bespalov participated in the meeting "Current issues in the preclinical and clinical research on novel drugs, biomedical cell products and medical devices" in St Petersburg.  This meeting held for the fifth time is a unique opportunity for the academic and industrial researchers and organizations (including CROs and SMEs) to meet regulators and funding agencies and in an informal manner discuss the real issues. Anton Bespalov presented a plenary lecture on the "Low-burden quality management system for nonclinical drug discovery research".


October 27, 2016

Kick-off Meeting on Good Research Practice

The ECNP Network "Preclinical Data Forum" held a meeting with different stakeholders from academia, industry, publishers and funding organisations to identify needs to set up Good Research Practice Guidelines. This first meeting was held in Amsterdam and aimed to identify the baseline for these guidelines (e.g. what is in place already), missing partners or organisations, which are obstacles that can be expected and need to be addressed, and finally identify key tools and players having the power to "enforce" implementation of the standards.


September 21-23, 2016

21. Jahrestagung der Deutschen Gesellschaft für Gute Forschungspraxis

During this years annual congress of the DGGF, Christoph gave a presentation about Good Research Practice - Quality governance in pre-clinical biomedical research.


September 20, 2016

Two reproducibility symposia held during the 29th annual congress of European College of Neuropsychopharmacology (LINK)

For a number of years, much of the so called reproducibility discussion was largely limited to describing this phenomenon of strikingly low robustness of preclinical data. Focus of the discussion is shifting now towards identification of the measures that can be taken at different levels – from scientists to publishers – to change the situation. During these two symposia, there were a number of talks that discussed strategies that can be followed by publishers and editors (Mark Weiser, Tel-Aviv University), role of an adequate statistical power (Marcus Munafo, Bristol University), efforts by pharma industry (Thomas Steckler, Janssen) and funding agencies (Frances Rawle, UK Medical Research Council, LINK), etc. 

Talk by Anton Bespalov addressed „Path forward strategies to improved data quality in preclinical research“. In his talk, Anton emphasized what can be done by individual scientists today and without any additional financial support: revisiting the basics of good scientific practice (such as the statistical power - LINK), adhering to transparent reporting, and not hesitating to seek professional advice when needed (most importantly, working in a close collaboration with biostatistics experts).


June 15-18, 2016

2nd Central European Biomedical Congress

Anton gave the Plenary Lecture 5 at the 2nd Central European Biomedical Congress which was held in Krakow from 15-18 June (link to program). He discussed an Industry perspective on how novel new drug targets need to be. Please do not hesitate to sent a short email if you have any questions about the presentation or just want to discuss some topics we are concerned about, e.g. How to improve drug discovery by using effective quality concepts.